Ozempic & GLP-1 Lawsuit Overview
Ozempic (semaglutide) is a GLP-1 receptor agonist medication manufactured by Novo Nordisk, originally approved by the FDA in 2017 for the treatment of type 2 diabetes. A higher-dose version, Wegovy, was approved in 2021 specifically for chronic weight management. These medications, along with Eli Lilly's competing drug Mounjaro (tirzepatide), have experienced explosive growth in prescriptions due to their effectiveness for weight loss. However, mounting evidence suggests these drugs carry serious risks of severe gastrointestinal injuries that were not adequately disclosed to patients or prescribing physicians.
The most concerning adverse effect is gastroparesis, also known as stomach paralysis, a condition in which the stomach muscles stop functioning properly and cannot move food through the digestive tract normally. Patients with gastroparesis experience severe nausea, vomiting, abdominal pain, bloating, and malnutrition. In serious cases, gastroparesis can become a chronic, debilitating condition requiring hospitalization, surgical intervention, or long-term medical management. Additional serious gastrointestinal injuries linked to GLP-1 drugs include intestinal obstruction, pancreatitis, gallbladder disease, and bowel obstruction.
Thousands of lawsuits have been filed against Novo Nordisk and Eli Lilly alleging that these manufacturers failed to adequately warn about the risk of severe gastrointestinal complications. A federal multidistrict litigation (MDL) has been established in the Eastern District of Pennsylvania to consolidate and manage the growing number of GLP-1 injury claims. Plaintiffs allege that the companies prioritized aggressive marketing and massive profits over patient safety, and that the drug labels should have included stronger and more specific warnings about gastroparesis and related conditions.
Gastroparesis and Other Serious Side Effects
Gastroparesis, or stomach paralysis, occurs when the nerves and muscles of the stomach fail to contract properly, significantly delaying or preventing the emptying of stomach contents into the small intestine. GLP-1 receptor agonists like semaglutide work in part by slowing gastric emptying to promote feelings of fullness and reduce appetite. However, in some patients, this mechanism can cause pathological levels of gastric slowing that result in a clinical diagnosis of gastroparesis. Symptoms include persistent nausea, repeated vomiting of undigested food, severe abdominal pain, bloating, early satiety, and significant weight loss due to inability to maintain adequate nutrition.
Research and adverse event data have linked Ozempic, Wegovy, Mounjaro, and other GLP-1 medications to additional serious gastrointestinal injuries. Pancreatitis, an inflammation of the pancreas that can be life-threatening, has been reported in GLP-1 drug users at rates that concern medical researchers. Gallbladder disease, including gallstones and cholecystitis requiring surgical removal of the gallbladder, has also been associated with these medications. Intestinal obstruction, a potentially life-threatening condition requiring emergency surgery, has been reported as well. Some patients have developed cyclic vomiting syndrome, a chronic condition characterized by recurring episodes of severe vomiting.
A significant concern raised in the litigation is that many of these gastrointestinal complications may persist even after patients discontinue the medication. Because semaglutide and tirzepatide have long half-lives and remain active in the body for extended periods, their effects on gastric motility may continue for weeks or months after the last dose. Some patients have reported that their gastroparesis symptoms became permanent, fundamentally altering their ability to eat normally, maintain employment, and enjoy daily activities.
Who May Qualify for an Ozempic Lawsuit
You may be eligible to file a GLP-1 injury lawsuit if you used Ozempic, Wegovy, Mounjaro, Rybelsus, or another GLP-1 receptor agonist and experienced serious gastrointestinal complications. The following criteria are typically evaluated:
- 1GLP-1 Medication Use
You must have been prescribed and used a GLP-1 receptor agonist medication such as Ozempic, Wegovy, Mounjaro, or Rybelsus. Pharmacy records, insurance claims, and medical records can verify your medication history.
- 2Qualifying Injury
You must have been diagnosed with or treated for gastroparesis, intestinal obstruction, pancreatitis, gallbladder disease requiring surgery, severe vomiting requiring hospitalization, or another serious gastrointestinal complication. Medical records documenting the diagnosis and treatment are essential.
- 3Causal Connection
The injury should have occurred during or after your use of the GLP-1 medication. Medical opinions linking the medication to your condition strengthen the case. Prior gastrointestinal conditions may be considered but do not necessarily disqualify a claim if the medication worsened your condition.
- 4Measurable Damages
You must have suffered damages including medical expenses, hospitalization costs, lost wages, pain and suffering, or diminished quality of life as a result of the injury.
Ozempic MDL and Litigation Updates (2026)
The GLP-1 receptor agonist litigation has consolidated into a federal multidistrict litigation (MDL) in the Eastern District of Pennsylvania, designated as In Re: Ozempic (Semaglutide) and Mounjaro (Tirzepatide) Products Liability Litigation. This MDL consolidates claims from across the country for coordinated pretrial proceedings, including discovery, expert witness designations, and potential bellwether trials. The number of cases in the MDL has grown rapidly, reflecting the widespread use of these medications and the severity of reported injuries.
Plaintiffs' attorneys have obtained internal documents from Novo Nordisk and Eli Lilly through the discovery process, and these materials are expected to play a central role in upcoming bellwether trials. Key issues in the litigation include whether the manufacturers knew about the gastroparesis risk before marketing the drugs, whether the drug labels adequately warned about the severity and duration of gastrointestinal side effects, and whether the companies engaged in misleading promotional practices that downplayed known risks while promoting off-label weight loss use.
Ozempic and Wegovy generated over $18 billion in revenue for Novo Nordisk in 2024, while Mounjaro brought in over $12 billion for Eli Lilly. These massive revenue figures underscore the financial incentives at play and the potential magnitude of damages if the litigation results in substantial verdicts or settlements. Legal analysts anticipate that the GLP-1 litigation could become one of the largest pharmaceutical mass tort actions in U.S. history.
How to File an Ozempic Injury Claim
The first step in filing an Ozempic or GLP-1 injury claim is to consult with a pharmaceutical injury attorney who is experienced in mass tort litigation. During the initial consultation, which is typically free, the attorney will review your medication history, medical records, and injury documentation to assess whether you have a viable claim. If the attorney determines your case has merit, they will begin gathering the evidence needed to support your claim.
Your attorney will collect comprehensive documentation including pharmacy records showing your GLP-1 prescriptions, medical records documenting your gastrointestinal diagnosis and treatment, hospital records if you were admitted, and any records of communication with your doctor about side effects. Expert medical opinions may be obtained to establish the causal relationship between the medication and your injury. Your complaint will then be filed and likely transferred to the MDL for coordinated proceedings.
GLP-1 injury attorneys work on a contingency fee basis, so there is no upfront cost to you. The statute of limitations varies by state but generally ranges from two to four years from the date of injury or discovery of the connection between the medication and your condition. Given the active state of the litigation and the potential for settlement programs to be established, acting promptly is advisable to ensure your claim is filed within the applicable deadline.
FDA Safety Communications and Warning History
The FDA has issued several safety communications and label updates related to GLP-1 receptor agonist medications. The original Ozempic label included warnings about pancreatitis and thyroid C-cell tumors, but plaintiffs argue that warnings about gastroparesis and severe gastrointestinal events were insufficient. In September 2023, the FDA updated the Ozempic and Wegovy labels to include ileus (intestinal blockage) as a reported adverse event, following a growing number of post-marketing reports.
The FDA Adverse Event Reporting System (FAERS) has received thousands of reports of serious gastrointestinal events associated with semaglutide and tirzepatide products. These reports include cases of gastroparesis, intestinal obstruction, pancreatitis, and gallbladder disease, as well as reports of severe dehydration and kidney injury secondary to persistent vomiting. Plaintiffs' attorneys argue that the volume and severity of these reports demonstrate that the manufacturers should have provided stronger warnings much earlier.
Despite ongoing safety concerns, GLP-1 medications remain among the most prescribed drugs in the United States. The FDA continues to monitor safety data and may issue additional warnings or label changes as more information becomes available. Patients currently using these medications who experience concerning gastrointestinal symptoms should contact their healthcare provider promptly and report adverse events to the FDA MedWatch program.